KURAKura Oncology, Inc.

$815M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$34M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$426M

Total Liabilities

$31M

Stockholders' Equity

$395M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$33M	-11.5%
Net Income	-$34M	-$32M	-5.0%

KURA Q1 2023 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena